Search Header Logo

IMpower 110

Authored by SHANSHAN CHEN

Specialty

Professional Development

Used 4+ times

IMpower 110
AI

AI Actions

Add similar questions

Adjust reading levels

Convert to real-world scenario

Translate activity

More...

    Content View

    Student View

11 questions

Show all answers

1.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

在IMpower110研究中,对照组的化疗方案为

Carboplatin/cisplatin + paclitaxel/nab- paclitaxel

Carboplatin/cisplatin + pemetrexed/gemcitabine

Carboplatin/cisplatin + etoposide

Docetaxel

2.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

在IMpower110研究层级检验中,首先对哪种人群进行检验

TC1/2/3 or IC1/2/3(including EGFR+ or ALK+NSCLC)

TC3 or IC3(including EGFR+ or ALK+NSCLC)

TC1/2/3 or IC1/2/3(excluding EGFR+ or ALK+NSCLC)

TC/3 or IC3(excluding EGFR+ or ALK+NSCLC)

3.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

在IMpower110研究中, Atezolizumab单药对比化疗在TC3/IC3亚组中位OS有多长时间的改善?

5.1m

6.1m

7.1m

8.1m

4.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

在IMpower110研究中,Atezolizumab单药对比化疗无论在鳞癌还是非鳞癌,OS HR都在Atezolizumab单药组更优

True

False

5.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

1. 在IMpower110研究中,Atezolizumab单药在TC3/IC3 WT亚组人群中的12个月PFS率为多少?

9.9%

19.9%

26.9%

36.9%

6.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

在IMpower110研究中, Atezolizumab单药组发生的AE中需要应用皮质醇激素干预治疗的比例有多少?

<10%

10-20%

20-30%

>30%

7.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

在IMpower110研究中,对照组大约有多少比例的患者接受了后线的CIT治疗?

20%

30%

40%

15%

Access all questions and much more by creating a free account

Create resources

Host any resource

Get auto-graded reports

Google

Continue with Google

Email

Continue with Email

Classlink

Continue with Classlink

Clever

Continue with Clever

or continue with

Microsoft

Microsoft

Apple

Apple

Others

Others

Already have an account?